Allergic Immunotherapy Market is likely to grow at a CAGR of 8% by 2023

Pune, India, 2017-Jul-17 — /EPR Network/ —Allergy Immunotherapy is the treatment to minimize the sensitivity of the body and hence also knows as desensitization. During last few decades there has a dramatic increase in the frequency of the different allergy diseases. According to World Allergy Organization, 35-40 % of the total world population is suffering from major or minor type of allergy. Beside this they also stated that in rhinitis and allergic asthma are the major symptoms of allergy. Around 10 – 20% of the world population is suffers from rhinitis and allergic asthma. They are becoming the most common among youth.

There are different types of allergens which include smoke, food, medication or climate which may cause eczema, rhinitis, asthma or conjunctivitis. Environmental changes, increasing pollution, aging global population and increasing attention toward research of this conditions has driven he market. On Other hand increasing side effect and high cost associated with therapy may hamper the growth of the market.

Request a Sample Report @ https://www.marketresearchfuture.com/sample_request/1517

Competitive Analysis

• Sementis (Australia),
• Biomay AG (Austria),
• ALK-Abello Inc. (Denmark),
• Stallergenes SA (UK),
• Adamis Pharmaceuticals Corporation (US),
• DBV Technologies (France),
• Aimmune Therapeutics (U.S),
• ASIT biotech (Belgium),
• Laboratorios LETI (Spain),

Biomay AG (Austria), Merck Group (Germany), HAL Allergy Group (Netherland), Circassia (US), Anergis S.A. (Switzerland), Genentech, Inc. (US), Shionogi (Japan), MitsubishiTanabe Pharma (Japan), Allergy Therapeutics (UK), Tunitas Therapeutics (US), Nycomed (Switzerland), VentiRx Pharmaceuticals Inc. (US).

Many factors are fueling the growth of the market. This has attracted many of the manufacturer for development of the market in this sector. Increasing in alliances amongst the leading player has helped to introduction of new and better treatment for the allergy.

Allergy Therapeutics which is an UK based company has acquired Alerpharma S.A. in 2015 to expand its allergy immunotherapy market. In 2016, allergy immune therapy market was grown up by 16 % compare with 2015.

In 2016, Pfizer Inc. is merged with Allergan plc. to expand the market share in global market. Clinical trials results for PF-6444753 which is Immunoglobulin E vaccine for treatment of asthma is presented by company and is expecting that the it will launch in the market very soon. Alavert Odt, Ansaid and Vistaril are the common drugs used for the allergic treatment.

ALK-Abello Inc, this year announces that ACARIZAX®, sublingual allergy immunotherapy tablet used in treatment of allergy in adolescent patients has approved in 12 European countries. The results show that the safety, efficacy and tolerability profile of ACARIZAX® is better than the previous treatment.

Taste the market data and market information presented through more than 50 market data tables and figures spread in 80 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Allergy immunotherapy Market Research Report- Forecast To 2027”

Report Details @ https://www.marketresearchfuture.com/reports/allergy-immunotherapy-market-1517  

Regional Analysis

Geographically, Global Allergy immunotherapy Market is segmented as North America, Europe, Asia Pacific and Middle East and Africa. Majority of the market is dominated by North America and Europe. People more than 45 – 50 yrs. are more prone for allergy. North America and Europe together account a huge aging population. Beside these different government initiatives for research in this area has capture attention of many manufacturer. Asia pacific is the immerging market for the allergy immunotherapy. Due to a huge population base in this region and great pace of development has led to grow this market at fastest rate.

Segmentation:

Global Allergy immunotherapy Market is segmented on the basis of drug treatment which includes specific immunotherapy, and non-specific immunotherapy. Non-specific immunotherapy is further sub segmented into antihistamines, corticosteroids, mast cell stabilizers, epinephrine and other. on the basis of type of administration they are segmented as subcutaneous immunotherapy, sublingual immunotherapy and oral. On the basis of application they are segmented as asthma, conjunctivitis, skin allergy and others. On the basis of end user they are segmented as hospital, clinics and other.

Make an Enquiry @ https://www.marketresearchfuture.com/enquiry/1517

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact:

Akash Anand,

Market Research Future

+1 646 845 9312

Email: akash.anand@marketresearchfuture.com